Cambridge Investment Research Advisors’s Galmed Pharmaceuticals GLMD Stock Holding History

Cambridge Investment Research Advisors’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,132	Closed	-$19K	–	3768
2025 Q2	$19K	Buy	+10,132	New	+$14.9K	﹤0.01%	3581
2023 Q2	–	Sell	-158	Closed	-$12K	–	3226
2023 Q1	$12K	Hold	158	–	–	﹤0.01%	3128
2022 Q4	$14K	Sell	158 -37	-19%	-$2.42K	﹤0.01%	3069
2022 Q3	$11K	Buy	195 +44	+29%	+$3.75K	﹤0.01%	3021
2022 Q2	$18K	Buy	151 +6	+4%	+$994	﹤0.01%	3005
2022 Q1	$42K	Buy	+145	New	+$41.1K	﹤0.01%	3088

Other funds holding GLMD

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return

Cambridge Investment Research Advisors's GLMD Position: Q3 2025 in Review

Cambridge Investment Research Advisors sold out of Galmed Pharmaceuticals (GLMD) in Q3 2025, closing a stake of 10,132 shares — an estimated $19K sold.

Cambridge Investment Research Advisors first reported a position in GLMD in Q1 2022 and held it in 6 quarters. The position peaked at $42K in Q1 2022. 14 funds tracked by Wall St. Rank hold GLMD as of Q3 2025.

Cambridge Investment Research Advisors reported no remaining Galmed Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Cambridge Investment Research Advisors sold 10,132 Galmed Pharmaceuticals shares in Q3 2025, an estimated $19K.
Cambridge Investment Research Advisors first reported a position in Galmed Pharmaceuticals in Q1 2022 and held it in 6 quarters.
Cambridge Investment Research Advisors's Galmed Pharmaceuticals position peaked at $42K in Q1 2022.
14 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q3 2025.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2025, filed 12 Nov 2025.